NOAC dosage for patients undergoing cardioversion for atrial fibrillation

Join Professor John Camm and Dr Michael Ezekowitz for a discussion of the optimal anticoagulation strategy for a real-life patient case undergoing cardioversion for atrial fibrillation.

Speaker

Dr Michael Ezekowitz

Thomas Jefferson University & Lankenau, Bryn Mawr and Paoli Hospitals

Pennsylvania, USA

Topic

In this video, filmed at ACC 2018, Professor John Camm and Dr Michael Ezekowitz discuss the case of a 78-year old male with well-controlled hypertension who presented to the emergency department with palpitations. Discover the anticoagulation approach taken for this patient after an EKG confirmed atrial fibrillation and a cardioversion was planned. The risks and benefits of warfarin versus non-vitamin K oral anticoagulants (NOACs) are also explored, before an in-depth discussion into the optimal NOAC dosage before and after cardioversion.

• Target audience

  This educational activity is designed for hospitalists, haematologists, interventional cardiologists, internists/physicians, surgeons and any other healthcare professional with an interest or role in the management of patients on anticoagulation undergoing cardioversion for atrial fibrillation.

• Learning objectives

  After completing this educational activity, participants should be able to:

  • Understand the rationale for using non-vitamin K antagonist oral anticoagulants (NOACs) as anticoagulation therapy for cardioversion in patients who present with early onset atrial fibrillation (AF)
  • Select optimal NOAC dosage before and after cardioversion based on clinical and patient parameters
  • Recall the key trials evaluating NOACS in patients undergoing cardioversion for AF: dabigatran (RE-LY); rivaroxaban (X-VeRT); apixaban (EMANATE); and edoxaban (ENSURE-AF)
• Disclosures

  Professor John Camm, St George’s University of London, London, UK

  • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
  • Consultant (retained) for: Boehringer Ingelheim
  • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer

  Dr Michael Ezekowitz, Jefferson Medical College, Pennsylvania, USA

  • Receipt of grants/research supports from Boehringer Ingelheim
  • Receipt of honoraria/consultation fees from Boehringer Ingelheim, Pfizer, BMS, Daiichi Sankyo

  Staff and reviewer disclosures

  PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

• Funding

  This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.